Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2003
11/04/2003US6642210 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
11/04/2003US6642201 Use of a dipeptide for stimulating repair processes
11/04/2003US6642049 Human brain endothelial cells and growth medium and method for expansion of primitive CD34+CD38-bone marrow stem cells
11/04/2003US6642038 GlcNAc phosphotransferase of the lysosomal targeting pathway
11/04/2003US6642028 Isolated DNA encoding a Factor VIII protein; consensus splice sites which have been corrected relative to those of given nucleotide sequence
11/04/2003US6642023 High molecular weight; encoded by isolated nucleic acid; expression vectors; use for diagnostics, prophylaxis and treatment of infections
11/04/2003US6642011 Reducing allegenic response heterologous proteins; obtain nucleotide sequences of heterologous protein, insert subtilisin sequences, transform cell, expression vector, recover protein, monitor human to protein
11/04/2003US6642010 Identifying, monitoring, and treating women for breast precancer or cancer
11/04/2003US6641810 Methods of using geldanamycin and FK506 to treat peripheral nerve damage
11/04/2003US6641808 Composition for treatment of obesity
11/04/2003US6641618 Ready-to-use aqueous composition for bleaching keratin fibers, comprising a combination of a water-soluble solvent and a nonionic and/or anionic amphiphilic polymer comprising at least one fatty chain
11/04/2003US6641571 Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
11/04/2003CA2266006C Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists
11/04/2003CA2257322C Thiazole derivatives
11/04/2003CA2094773C 2,4-dioxoimidazolidine derivatives
10/2003
10/31/2003CA2444598A1 Compositions useful as inhibitors of gsk-3
10/30/2003WO2003089933A1 Uses of the carbamoyl phosphate synthesis 1 (cps 1) and the fragments thereof for the diagnosis of inflammatory diseases and sepsis
10/30/2003WO2003089903A2 Compositions and methods relating to endothelial cell signaling using the protease activated receptor (par1)
10/30/2003WO2003089638A1 Nucleic acid molecule encoding a variant ddah 1 protein and uses thereof
10/30/2003WO2003089615A2 Antiviral inhibitions of capsid proteins
10/30/2003WO2003089596A2 Novel prostate tumor-specific promoter
10/30/2003WO2003089593A2 Adjuvant enhanced immunotherapy
10/30/2003WO2003089569A2 Use of il-19, il-22 and il-24 to treat hematopoietic disorders
10/30/2003WO2003089439A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and method for the production thereof
10/30/2003WO2003089438A1 Labeled oxazinocarbazoles as diagnostic agents
10/30/2003WO2003089434A2 IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF
10/30/2003WO2003089429A1 Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one
10/30/2003WO2003089428A1 Tricyclic thrombin receptor antagonists
10/30/2003WO2003089427A1 Indol-2-ones as selective inhibitors of cyclooxygenase-2
10/30/2003WO2003089426A1 Medicine for prevention and/or therapy of disseminated intravascular coagulation syndrome
10/30/2003WO2003089425A1 Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-$g(a), $g(a)-dimethyl-benzeneacetic
10/30/2003WO2003089419A1 New 2-substituted -1,3-thiazole compounds
10/30/2003WO2003089411A1 Derivatives of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics
10/30/2003WO2003089410A1 Phenylalanine derivative
10/30/2003WO2003089409A1 Compounds having affinity at 5ht2c receptor and use thereof in therapy
10/30/2003WO2003089405A1 Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition
10/30/2003WO2003089007A1 Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu
10/30/2003WO2003089005A1 Drugs for treating vascular diseases
10/30/2003WO2003089002A1 Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia
10/30/2003WO2003088992A1 Novel screening method
10/30/2003WO2003088986A1 Curcumin for the prevention and/or treatment of tissue damage
10/30/2003WO2003088984A1 Compositions and methods for augmenting kidney function
10/30/2003WO2003088978A1 Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
10/30/2003WO2003088976A1 Method for treating and preventing hyperparathyroidism
10/30/2003WO2003088972A1 Novel compounds
10/30/2003WO2003088971A1 Combination therapy for the treatment of cancer
10/30/2003WO2003088970A2 Modulators of hedgehog signaling pathways, compositions and uses related thereto
10/30/2003WO2003088965A1 Use of materials having zinc ionophoric behavior
10/30/2003WO2003088961A1 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
10/30/2003WO2003088959A2 Treatment of parkinson's disease with cyclooxygenase-2 (cox 2) inhibitor(s)
10/30/2003WO2003088958A2 Combinations of cox-2 inhibitors and other agents for the treatment of parkinson’s disease
10/30/2003WO2003088944A1 Dry powder inhalant composition
10/30/2003WO2003088927A2 Novel curcumin analogues and uses thereof
10/30/2003WO2003088915A2 Novel sodium channel blockers
10/30/2003WO2003088908A2 Heterocyclo inhibitors of potassium channel function
10/30/2003WO2003088904A2 Screening and therapeutic methods for treating circadian rhythm disorders
10/30/2003WO2003088903A2 Compounds, compositions, and methods
10/30/2003WO2003088900A2 Solid forms of salts with tyrosine kinase activity
10/30/2003WO2003088898A2 Compositions and methods for the diagnosis and treatment of tumor
10/30/2003WO2003088761A2 Physiologically compatible, phospholipid-containing, stable and hard matrix
10/30/2003WO2003073841A3 Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
10/30/2003WO2003066579A3 Novel bicyclic hydroxamates as inhibitors of histone deacetylase
10/30/2003WO2003063796A3 Heterocyclic arylsulfonamidobenzylic compounds
10/30/2003WO2003057919A3 The use of histamine h4 receptor antagonist for the treatment of inflammatory response
10/30/2003WO2003057837A8 Methods for using anti-muc18 antibodies
10/30/2003WO2003053365A3 Syn3 compositions and methods
10/30/2003WO2003053353A3 Administration of vasopeptidase inhibitors to reduce pulse pressure
10/30/2003WO2003053330A3 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3
10/30/2003WO2003051833A3 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
10/30/2003WO2003051831A3 Protease inhibitors of the coagulation cascade isolated from dysidea sponges
10/30/2003WO2003051277A3 Novel compounds
10/30/2003WO2003049680A3 Compositions containing both sedative and non-sedative antihistamines
10/30/2003WO2003048148A3 Statin-like compounds
10/30/2003WO2003047697A3 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
10/30/2003WO2003047633A3 Treatment of angiogenesis disorders using targeted nanoparticles
10/30/2003WO2003045404A3 Treatment and diagnosis of diseases associated with adverse levels of zinc, cadmium and calcium
10/30/2003WO2003045319A3 Targeted therapeutics and uses thereof
10/30/2003WO2003040310A3 Novel epidermal growth factor protein and gene, and methods of use therefor
10/30/2003WO2003039545A3 Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
10/30/2003WO2003039491A8 Novel isoforms of vascular endothelial cell growth inhibitor
10/30/2003WO2003034903A3 Psma antibodies and protein multimers
10/30/2003WO2003032921A3 Treatment of neurodegenerative diseases and cancer of the brain
10/30/2003WO2003029428A3 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease
10/30/2003WO2003029264A3 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
10/30/2003WO2003025199A3 Mid 4460, a human tyrosine phosphatase family member and uses therefor
10/30/2003WO2003024455A3 Stent coated with a sustained-release drug delivery and method for use thereof
10/30/2003WO2003024436A3 Method for treating skin disorders
10/30/2003WO2003022243A3 Sustained release of microcrystalline peptide suspensions
10/30/2003WO2003020287A3 Methods for the treatment of chronic pain anc compositions therefor
10/30/2003WO2003016549A3 Nucleic-acid associated proteins
10/30/2003WO2003015608A3 Combination therapy for the treatment of cancer
10/30/2003WO2003012051A3 Inhibitor of dna methylation
10/30/2003WO2003011881A3 Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain
10/30/2003WO2003008635A8 η-SECRETASE IN VITRO SCREENING ASSAY
10/30/2003WO2003004501A3 (hetero) aryl substituted benzofurans as 5-ht ligands
10/30/2003WO2002102777A8 NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE
10/30/2003WO2002102229A3 Diagnosing tumorigenicity and determining resistance to anticancer therapy
10/30/2003WO2002099041A3 Ces2s as modifiers of the p53 pathway and methods of use
10/30/2003WO2002097030A3 Peptides derived from neural thread proteins and their medical use
10/30/2003WO2002094876A3 Methods and compositions for treating respiratory mucin production associated disease conditions
1 ... 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 ... 1564